GCA
BIO icon

Gideon Capital Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Gideon Capital Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,761
Closed -$538K – 281
2019
Q1 		$538K Buy
+1,761
New +$475K 0.19% 153
2018
Q3 		– Sell
-1,236
Closed -$357K – 350
2018
Q2 		$357K Sell
1,236
-1,101
-47% -$304K 0.18% 215
2018
Q1 		$584K Buy
+2,337
New +$595K 0.36% 89

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Gideon Capital Advisors's BIO Position: Q2 2019 in Review

Gideon Capital Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2019, closing a stake of 1,761 shares — an estimated $538K sold.

Gideon Capital Advisors first reported a position in BIO in Q1 2018 and held it in 3 quarters. The position peaked at $584K in Q1 2018. 330 funds tracked by Wall St. Rank hold BIO as of Q2 2019.

  • Gideon Capital Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q2 2019 after selling out during the quarter.
  • Gideon Capital Advisors sold 1,761 Bio-Rad Laboratories Class A shares in Q2 2019, an estimated $538K.
  • Gideon Capital Advisors first reported a position in Bio-Rad Laboratories Class A in Q1 2018 and held it in 3 quarters.
  • Gideon Capital Advisors's Bio-Rad Laboratories Class A position peaked at $584K in Q1 2018.
  • 330 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2019.

Based on Gideon Capital Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.